US Commercial Pharmaceutical Analytics Market

ID: MRFR/HCIT/11582-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
US Commercial Pharmaceutical Analytics Market Research Report: By Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics), By Application (R&D, Marketing & Sales, Supply Chain Optimization, Internal Reporting), By Deployment (On-Premise, Web-Based/Cloud-Based) and By Components (Software, Services) - Growth & Industry Forecast 2025 To 2035
US Commercial Pharmaceutical Analytics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.57%
2024 Market Size$ 6.96 Billion
2025 Market Size$ 7.35 Billion
2035 Market Size$ 12.63 Billion
Key Players
IQVIA
Thermo Fisher Scientific
AbbVie
Roche
Merck KGaA
Pfizer
Opportunities
  • Increased Investment in R&D
  • Integration of Advanced Technologies
  • Rising Demand for Data-Driven Insights
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Type (USD Billion)
      1. 4.1.1 Descriptive Analytics
      2. 4.1.2 Predictive Analytics
      3. 4.1.3 Prescriptive Analytics
    2. 4.2 Construction, BY Application (USD Billion)
      1. 4.2.1 R&D
      2. 4.2.2 Marketing & Sales
      3. 4.2.3 Supply Chain Optimization
      4. 4.2.4 Internal Reporting
    3. 4.3 Construction, BY Deployment (USD Billion)
      1. 4.3.1 On-Premise
      2. 4.3.2 Web-Based/Cloud-Based
    4. 4.4 Construction, BY Components (USD Billion)
      1. 4.4.1 Software
      2. 4.4.2 Services
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 IQVIA (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Thermo Fisher Scientific (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AbbVie (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Roche (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck KGaA (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novartis (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bristol-Myers Squibb (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Amgen (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY DEPLOYMENT
    5. 6.5 US MARKET ANALYSIS BY COMPONENTS
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Billion)
    16. 6.16 CONSTRUCTION, BY DEPLOYMENT, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY DEPLOYMENT, 2024 TO 2035 (USD Billion)
    18. 6.18 CONSTRUCTION, BY COMPONENTS, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY COMPONENTS, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY DEPLOYMENT, 2025-2035 (USD Billion)
      4. 7.2.4 BY COMPONENTS, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Commercial Pharmaceutical Analytics Market Segmentation

US Commercial Pharmaceutical Analytics Market By Type (USD Billion, 2025-2035)

  • Descriptive Analytics
  • Predictive Analytics
  • Prescriptive Analytics

US Commercial Pharmaceutical Analytics Market By Application (USD Billion, 2025-2035)

  • R&D
  • Marketing & Sales
  • Supply Chain Optimization
  • Internal Reporting

US Commercial Pharmaceutical Analytics Market By Deployment (USD Billion, 2025-2035)

  • On-Premise
  • Web-Based/Cloud-Based

US Commercial Pharmaceutical Analytics Market By Components (USD Billion, 2025-2035)

  • Software
  • Services
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.